Nature: ignored for 30 years! Key peptides of Alzheimer's disease

September 8, 2015 / BIOON / -- recently, in a research paper published in the international journal Nature, from Ludwig Maximilian University of Munich's researchers identified a new type of peptide, which plays an important role in the pathogenesis of Alzheimer's disease The researchers found that the previously neglected ETA amyloid protein can interfere with the function of neurons and neutralize β - amyloid protein, which may be helpful for clinical trials Alzheimer's disease is mainly manifested in the accumulation of special neurotoxic proteins in multiple regions of the brain The chemical analysis of these insoluble accumulating proteins reveals that they are composed of a family of short protein fragments, known as β - amyloid peptide, derived from a precursor protein called app In this paper, the researchers clarified the pathogenesis of Alzheimer's disease, This provides a certain basis for understanding the pathogenesis of the disease and developing new therapies The researchers pointed out that the existence of the second division mode of app can participate in some unknown division processes and produce an alternative peptide The researchers named this ETA amyloid protein "amyloid - η", and the process of producing this protein has been ignored for about 30 years This is because the researchers focus on clarifying the source of β - amyloid protein in the brain of Alzheimer's disease patients, and developing new strategies to inhibit the development of disease based on this β - amyloid protein Then the researchers tested the effect of ETA amyloid on the function of nerve cells in the brain We all know that β - amyloid can promote the over activity of nerve cells, but now researchers have found that ETA amyloid can resist the effect of resisting the increased activity Relevant research findings have certain significance for targeting β - amyloid protein in later human clinical trials For example, researchers can design β - secretory enzymes with pharmacological inhibition, which can release toxic β - amyloid protein, thereby reducing memory loss in Alzheimer's disease patients The researchers pointed out that blocking β - secretory The activity of enzyme may reduce the level of β - amyloid, but it will increase the production of ETA amyloid, which will eventually lead to the decrease of neuron activity and the neutralization of brain function; more research is needed to explain the role of this new peptide in Alzheimer's disease later This article is the original compilation of Biovalley, welcome to reprint! Please indicate the source of the reprint and attach the original link For more information, please download Biovalley app